CareCloud, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -73.5% over 5Y.
today you would have $269.03▼ -73.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 12 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.92 | $3.66 | $1.52 | $2.81 | $6.32 | $9.07 | $4.06 | $3.80 | $2.61 | $0.73 | $1.20 | $2.34 | |
| P/E | — | 29.2x | — | — | — | — | — | — | — |
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Square root of 22.5 × earnings × book value — the two ceilings Graham proposed. Blind to intangibles, so it undervalues software and brands.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Median P/E of 22.4 among peers in the sector.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 13.3x operating profit, less net debt. Sees the business before its financing, so debt does not distort the comparison. Banks have no EBITDA — interest is their revenue, not a cost.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| COYACoya Therapeutics, Inc. | $4.59 | — | 2.5x | — | -60.54% | $107.67M |
| CRDFCardiff Oncology, Inc. | $1.33 | — | 3.4x | — | -94.08% | $103.47M |
| PYPDPolyPid Ltd. | $5.07 | — | 19.1x | — | -243.59% | $102.98M |
| PLYXPolaryx Therapeutics, Inc. | $2.06 |
CareCloud, Inc., a healthcare information technology company, provides technology-enabled business solutions, Software-as-a-Service offerings, and related business services to healthcare providers and hospitals primarily in the United States. It operates through Healthcare IT and Medical Practice Management segments. The company's proprietary software and business services includes technology-enabled business solutions; cloud-based software; digital health services; healthcare IT professional services and staffing; MAP App; and medical practice management services. It also offers revenue cycle management services, healthcare claims clearinghouse, and medical coding and credentialing services; electronic health records, practice management software and related capabilities, patient experience management solutions, business intelligence and healthcare analytics platforms, and customized applications, interfaces, and various other technology solutions, as well as artificial intelligence, such as CareCloud cirrusAI, AI-powered clinical decision support, AI-powered virtual support assistant, AI-driven appeals, Stratus AI Desk Agent, and CareCloud cirrusAI. In addition, the company provides chronic care management, remote patient monitoring, and telemedicine solutions; professional services; managed services; workforce augmentation; on-demand staffing; and strategic advisory services. Further, it offers medical practice management services to medical practices comprising appropriate facilities, equipment, supplies, support services, nurses, and administrative support staff, as well as management, bill-paying, and financial advisory services. It serves physicians, nurses, nurse practitioners, therapists, physician assistants, and other clinicians that render bills for their services. The company was formerly known as MTBC, Inc. and changed its name to CareCloud, Inc. in March 2021. CareCloud, Inc. was founded in 1999 and is headquartered in Somerset, New Jersey.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| — |
| P/S | 0.8x | 1.0x | 1.4x | 0.2x | 0.3x | 0.7x | 1.2x | 0.8x | 0.9x | 1.0x | 0.3x | 0.5x | 1.4x |
| P/B | 1.2x | 2.1x | 3.1x | 0.6x | 0.4x | 1.0x | 1.3x | 1.2x | 1.2x | 1.5x | 1.1x | 0.8x | 1.8x |
| EPS | $0.10 | -$0.28 | -$4.11 | -$0.67 | -$0.77 | -$1.79 | -$0.60 | -$0.59 | -$0.69 | -$0.95 | — | -$0.64 |
| Profit margin | -6.31% | 8.96% | 7.08% | -41.58% | 3.91% | 2.03% | -8.38% | -1.35% | -4.23% | -17.49% | -35.91% | -20.31% | -24.64% |
| ROE | -7.10% | 18.15% | 15.77% | -116.68% | 5.34% | 2.90% | -8.70% | -2.04% | -5.50% | -27.48% | -124.48% | -31.48% | -31.49% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Not the average of the seven numbers above. Four of the seven start from the same earnings per share — Graham, Lynch, sector multiples and its own history — so averaging all seven would let one input count four times and drown out the others. Instead each family produces one number, and the fair price is the average of the families that answered. A family with two working formulas contributes their average, not two votes.
4 methods answered, across 3 families.
Every formula reads the same reported statements and they can be wrong together. The margin is room for that.
+150.2% from the average.
These are models, not forecasts, and not investment advice. Change one assumption and the number changes with it — that is a property of valuation, not a defect of this page.
| — |
| 9.4x |
| — |
| -96.56% |
| $102.68M |
| ONCYOncolytics Biotech Inc | $0.86 | — | — | — | — | $109.23M |
| LNSRLENSAR, Inc. | $8.30 | 41.5x | 6.8x | — | 357.30% | $101.97M |